Founded in 2018, Celadon Pharmaceuticals PLC (AIM: CEL) is a leader in the medical cannabis industry and has successfully paved the way with regulators to achieve EU-GMP approval for the production and supply of High-THC medical cannabis.
Celadon’s research has led to the first MHRA-approved clinical trial for chronic non-cancer pain in the UK using medicinal cannabis flowers and is dedicated to addressing unmet patient needs, pioneering new paths in healthcare innovation. At the core of Celadon lie our values of Patient first, Collaboration, Innovation and Determination.